Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Prachi Jain; Jeffrey Klotz; Neil Dunavin; Kit Lu; Eleftheria Koklanaris; Debbie Draper; Jeanine Superata; Fariba Chinian; Quan Yu; Keyvan Keyvanfar; Susan Wong; Pawel Muranski; A. John Barrett; Sawa Ito; Minoo Battiwalla

doi:10.1016/j.lrr.2017.04.003

Leukemia Research Reports (Jan 2017)

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Prachi Jain,
Jeffrey Klotz,
Neil Dunavin,
Kit Lu,
Eleftheria Koklanaris,
Debbie Draper,
Jeanine Superata,
Fariba Chinian,
Quan Yu,
Keyvan Keyvanfar,
Susan Wong,
Pawel Muranski,
A. John Barrett,
Sawa Ito,
Minoo Battiwalla

Affiliations

Prachi Jain: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Jeffrey Klotz: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Neil Dunavin: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Kit Lu: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Eleftheria Koklanaris: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Debbie Draper: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Jeanine Superata: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Fariba Chinian: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Quan Yu: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Keyvan Keyvanfar: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Susan Wong: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Pawel Muranski: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
A. John Barrett: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Sawa Ito: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Minoo Battiwalla: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

DOI: https://doi.org/10.1016/j.lrr.2017.04.003
Journal volume & issue: Vol. 7, no. C
pp. 40 – 44

Abstract

Read online

Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.

Published in Leukemia Research Reports

ISSN: 2213-0489 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/leukemia-research-reports/

About the journal

Abstract

Keywords